Tuesday, December 13, 2016

BRIEF-Dimension Therapeutics says FDA acceptance of investigational NDA for DTX301

* Dimension Therapeutics - anticipates commencing

multi-center Phase 1/2 clinical trial to evaluate DTX301 in

patients with OTC deficiency by end of 2016

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)